Guerbet

What they make

1 input Guerbet supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Origin2024

  Guerbet is, in effect, descended from the invention of contrast imaging itself. The company's lineage traces to Lipiodol — an iodized poppy-seed oil that became one of the first radiographic contrast agents in the early 20th century, letting doctors see structures on X-ray that were otherwise invisible. Remarkably, Lipiodol is still on the market today, used in specialized procedures like lymphatic imaging and the chemoembolization of liver tumors. From that origin Guerbet became a rare thing in modern medicine: a pure-play contrast-media company. Unlike its rivals — GE HealthCare (an imaging-equipment conglomerate) and Bayer (a pharma-and-agriculture giant) — Guerbet does essentially one thing, contrast and interventional imaging, which makes it the specialist fourth member of the GE/Bayer/Bracco/Guerbet oligopoly. Its entire corporate existence rests on a single essential medical category that the others treat as a sideline — a niche French company carrying a century-old heritage at the very birth of seeing inside the living body.

  Guerbet SA ↗

• Substitution2024

  Guerbet made an early bet that turned out to define modern MRI safety: its Dotarem (gadoterate meglumine) is a macrocyclic gadolinium contrast agent — the chemical class that wraps the toxic gadolinium ion in a closed, ring-shaped cage, holding it far more tightly than older "linear" agents. When evidence accumulated that gadolinium could be released and retained in patients' bodies (causing nephrogenic systemic fibrosis in those with kidney failure, and depositing in the brain), regulators and radiologists shifted decisively toward exactly this macrocyclic class, and some linear agents were restricted or withdrawn in Europe. So the safer chemistry the whole field moved to was one Guerbet had committed to early. It's a clean example of how a materials-safety discovery can reward the supplier that anticipated it — and of how the "dye" injected into millions of MRI patients quietly evolved, under regulatory pressure, toward molecules engineered to keep a poisonous rare-earth metal from ever coming loose inside the body. [verify: Guerbet Dotarem macrocyclic; field shift after gadolinium-retention evidence confirmed]

  Guerbet SA ↗